132 related articles for article (PubMed ID: 30458775)
1. BLASSO: integration of biological knowledge into a regularized linear model.
Urda D; Aragón F; Bautista R; Franco L; Veredas FJ; Claros MG; Jerez JM
BMC Syst Biol; 2018 Nov; 12(Suppl 5):94. PubMed ID: 30458775
[TBL] [Abstract][Full Text] [Related]
2. Incorporating prior biological knowledge for network-based differential gene expression analysis using differentially weighted graphical LASSO.
Zuo Y; Cui Y; Yu G; Li R; Ressom HW
BMC Bioinformatics; 2017 Feb; 18(1):99. PubMed ID: 28187708
[TBL] [Abstract][Full Text] [Related]
3. Network based consensus gene signatures for biomarker discovery in breast cancer.
Fröhlich H
PLoS One; 2011; 6(10):e25364. PubMed ID: 22046239
[TBL] [Abstract][Full Text] [Related]
4. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
5. Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA.
Paul MR; Levitt NP; Moore DE; Watson PM; Wilson RC; Denlinger CE; Watson DK; Anderson PE
BMC Genomics; 2016 Mar; 17():263. PubMed ID: 27029813
[TBL] [Abstract][Full Text] [Related]
6. Regularized logistic regression with network-based pairwise interaction for biomarker identification in breast cancer.
Wu MY; Zhang XF; Dai DQ; Ou-Yang L; Zhu Y; Yan H
BMC Bioinformatics; 2016 Feb; 17():108. PubMed ID: 26921029
[TBL] [Abstract][Full Text] [Related]
7. Dynamic incorporation of prior knowledge from multiple domains in biomarker discovery.
Guan X; Runger G; Liu L
BMC Bioinformatics; 2020 Mar; 21(Suppl 2):77. PubMed ID: 32164534
[TBL] [Abstract][Full Text] [Related]
8. Prediction of early breast cancer patient survival using ensembles of hypoxia signatures.
Gong IY; Fox NS; Huang V; Boutros PC
PLoS One; 2018; 13(9):e0204123. PubMed ID: 30216362
[TBL] [Abstract][Full Text] [Related]
9. Genes and functions from breast cancer signatures.
Huang S; Murphy L; Xu W
BMC Cancer; 2018 Apr; 18(1):473. PubMed ID: 29699511
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
11. Mixture classification model based on clinical markers for breast cancer prognosis.
Zeng T; Liu J
Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
[TBL] [Abstract][Full Text] [Related]
12. RNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin.
Wei IH; Shi Y; Jiang H; Kumar-Sinha C; Chinnaiyan AM
Neoplasia; 2014 Nov; 16(11):918-27. PubMed ID: 25425966
[TBL] [Abstract][Full Text] [Related]
13. DeepTRIAGE: interpretable and individualised biomarker scores using attention mechanism for the classification of breast cancer sub-types.
Beykikhoshk A; Quinn TP; Lee SC; Tran T; Venkatesh S
BMC Med Genomics; 2020 Feb; 13(Suppl 3):20. PubMed ID: 32093737
[TBL] [Abstract][Full Text] [Related]
14. Stable Gene Signature Selection for Prediction of Breast Cancer Recurrence Using Joint Mutual Information.
Sehhati M; Mehridehnavi A; Rabbani H; Pourhossein M
IEEE/ACM Trans Comput Biol Bioinform; 2015; 12(6):1440-8. PubMed ID: 26671813
[TBL] [Abstract][Full Text] [Related]
15. Including network knowledge into Cox regression models for biomarker signature discovery.
Fröhlich H
Biom J; 2014 Mar; 56(2):287-306. PubMed ID: 24430933
[TBL] [Abstract][Full Text] [Related]
16. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
[TBL] [Abstract][Full Text] [Related]
18. Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach.
Rakhshaninejad M; Fathian M; Shirkoohi R; Barzinpour F; Gandomi AH
BMC Bioinformatics; 2024 Jan; 25(1):33. PubMed ID: 38253993
[TBL] [Abstract][Full Text] [Related]
19. Accounting for grouped predictor variables or pathways in high-dimensional penalized Cox regression models.
Belhechmi S; Bin R; Rotolo F; Michiels S
BMC Bioinformatics; 2020 Jul; 21(1):277. PubMed ID: 32615919
[TBL] [Abstract][Full Text] [Related]
20. Improving the Robustness of Variable Selection and Predictive Performance of Regularized Generalized Linear Models and Cox Proportional Hazard Models.
Hong F; Tian L; Devanarayan V
Mathematics (Basel); 2023 Feb; 11(3):. PubMed ID: 37990696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
